Determination of 4-hydroxy-3-methoxymethamphetamine as a metabolite of methamphetamine in rats and human liver microsomes using gas chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry

Journal of Analytical Toxicology

Volumn 33, Issue 5, 2009, Pages 266-271

  Kuwayama, Kenji ^a   Tsujikawa, Kenji ^a   Miyaguchi, Hajime ^a   Kanamori, Tatsuyuki ^a   Iwata, Yuko T ^a   Inoue, Hiroyuki ^a  

^a NATIONAL RESEARCH INSTITUTE OF POLICE SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXY 3 METHOMETHAMPHETAMINE; AMPHETAMINE; METHAMPHETAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG URINE LEVEL; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; MASS FRAGMENTOGRAPHY; METABOLITE; NONHUMAN; RAT; TANDEM MASS SPECTROMETRY;

RATTUS;

EID: 68949130822     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/33.5.266     Document Type: Article

References (31)

1. National Police Agency of Japan. DRUG 2008. National Police Agency of Japan, Tokyo, Japan, 2008.
2. C. Davidson, A.J. Gow, T.H. Lee, and E.H. Ellinwood. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res. Rev. 36: 1-22 (2001).
3. G.R. Hanson, K.S. Rau, and A.E. Fleckenstein. The methamphetamine experience: a NIDA partnership. Neuropharmacology 47: 92-100 (2004).
4. M.J. Bogusz, R.D. Maier, K.D. Krüger, and U. Kohls. Determination of common drugs of abuse in body fluids using one isolation procedure and liquid chromatography-atmospheric-pressure chemicalionization mass spectromery. J. Anal. Toxicol. 22: 549-558 (1998).
5. M.J. Bogusz.Liquid chromatography-mass spectrometry as a routine method in forensic sciences: a proof of maturity. J. Chromatogr. B 748: 3-19 (2000).
6. H.S. Shin. Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites. Drug Metab. Dispos. 25: 657-662 (1997).
7. H. Kalant. The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. CMAJ 165: 917-928 (2001).
8. J. Lyles and J.L. Cadet. Methylenedioxymethamphetamine (MDMA, Ecstasy) neurotoxicity: cellular and molecular mechanisms. Brain Res. Rev. 42: 155-168 (2003).
9. J. Caldwell, L.G. Dring, and R.T. Williams. Metabolism of (14C)methamphetamine in man, the guinea pig and the rat. Biochem. J. 129: 11-22 (1972).
10. M.L. Forsling, J.K. Fallon, D. Shah, G.S. Tilbrook, D.A. Cowan, A.T. Kicman, and A.J. Hutt. The effect of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus. Br. J. Pharmacol. 135: 649-656 (2002).
11. J.K. Fallon, D. Shah, A.T. Kicman, A.J. Hutt, J.A. Henry, D.A. Cowan, and M. Forsling. Action of MDMA (ecstasy) and its metabolites on arginine vasopressin release. Ann. N.Y. Acad. Sci. 965: 399-409 (2002)
12. D.C. Jones, C. Duvauchelle, A. Ikegami, C.M. Olsen, S.S. Lau, R. de la Torre, and T.J. Monks. Serotonergic neurotoxic metabolites of ecstasy identified in rat brain. J. Pharmacol. Exp. Ther. 313: 422-431 (2005).
13. H. Helmlin, K. Bracher, D. Bourquin, D. Vonlanthen, R. Brenneisen, and J. Styk. Analysis of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS. J. Anal. Toxicol. 20: 432-440 (1996).
14. S. Pichini, M. Navarro, R. Pacifici, P. Zuccaro, J. Ortuño, M. Farré, P. Nolasc, J. Segura, and R. de la Torre. Usefulness of sweat testing for the detection of MDMA after a single-dose administration. J. Anal. Toxicol. 27: 294-303 (2003).
15. K. Nakashima. High-performance liquid chromatographic analysis of drugs of abuse in biologic samples J. Health Sci. 51: 272-277 (2005).
16. K.M. Jenkins, M.S. Young, and C.R. Mallet. Mixed-mode solidphase extraction procedures for the determination of MDMA and metabolites in urine using LC-MS, LC-UV, or GC-NPD. J. Anal. Toxicol. 28: 50-58 (2004).
17. M.J. Bogusz, K.D. Krüger, and R.D. Maier. Analysis of underivatized amphetamines and related phenethylamines with high-performance liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. J. Anal. Toxicol. 24: 77-84 (2000).
18. H. Hendrickson, E. Laurenzana, and S.M. Owens. Quantitative determination of total methamphetamine and active metabolites in rat tissue by liquid chromatography with tandem mass spectrometric detection. AAPS J. 22: E709-717 (2006).
19. A. Dasgupta, A. Hart, P. Humphrey, and W. Blackwell. Gas chromatography- electron ionization and chemical ionization mass spectrometric analysis of urinary phenmetrazine after derivatization with 4-carbethoxyhexafluorobutyryl chloride-a new derivative. J. Forensic Sci. 43: 636-640 (1998).
20. K. Kuwayama, H. Inoue, T. Kanamori, K. Tsujikawa, H. Miyaguchi, Y.T. Iwata, S. Miyauchi, and N. Kamo. Analysis of amphetaminetype stimulants and their metabolites in plasma, urine and bile by liquid chromatography with a strong cation-exchange columntandem mass spectrometry. J. Chromatogr. B 867: 78-83 (2008).
21. K. Tanaka, T. Inoue, and H. Ohki. Analysis of 3,4- methylenedioxymethamphetamine and its metabolites. Rep. Natl. Res. Inst. Police Sci. 41: 114-119 (1988).
22. T. Inoue and S. Suzuki. Studies on metabolism of methamphetamine analogs 6. Analysis of dimethylamphetamine and its metabolites. Rep. Natl. Res. Inst. Police Sci. 39: 228-234 (1986).
23. R. de la Torre, M. Farré, P.N. Roset, N. Pizarro, S. Abanades, M. Segura, J. Segura, and J. Camí. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther. Drug Monit. 26: 137-144 (2004).
24. B.T. Zhu. Catechol-O-Methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis. Curr. Drug Metab. 3: 321-349 (2002).
25. T. Müller, D. Woitalla, B. Hauptmann, B. Fowler, and W. Kuhn. Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease. Neurosci. Lett. 308: 54-56 (2001).
26. N. Shima, H.T. Kamata, M. Katagi, and H. Tsuchihashi.Urinary excretion of the main metabolites of methamphetamine, including p-hydroxymethamphetamine- sulfate and p-hydroxymethamphetamine-glucuronide, in humans and rats. Xenobiotica 36: 259-267 (2006).
27. N. Shima, M. Katagi, H. Kamata, K. Zaitsu, T. Kamata, M. Nishikawa, A. Miki, H. Tsuchihashi, T. Sakuma, and N. Nemoto. Urinary excretion of the main metabolites of 3,4-methylenedioxymethamphetamine (MDMA), including the sulfate and glucuronide of 4-hydroxy-3-methoxymethamphetamine (HMMA), in humans and rats. Xenobiotica 38: 314-324 (2008).
28. D. Wu, S.V. Otton, T. Inaba,W. Kalow, and E.M. Sellers. Interactions of amphetamine analogs with human liver CYP2D6. Biochem. Pharmacol. 53: 1605-1612 (1997).
29. M. Segura, M. Farré, S. Pichini, A.M. Peiró, P.N. Roset, A. Ramírez, J. Ortuño, R. Pacifici, P. Zuccaro, J. Segura, and R. de la Torre. Contribution of cytochrome P450 2D6 to 3,4- methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe. Clin. Pharmacokinet. 44: 649-660 (2005).
30. M.R. Meyer, F.T. Peters, and H.H. Maurer. The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4- methylenedioxy- methamphetamine and its enantiomers. Drug Metab. Dispos. 36: 2345-2354 (2008).
31. K. Kreth, K. Kovar, M. Schwab, and U.M. Zanger. Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs. Biochem. Pharmacol. 59: 1563-1571 (2000).